Yahoo · Oct 31, 2026
Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real?
Pfizer's post-COVID comeback is still only in the early stages.
NASDAQ · PFE
Pfizer Inc.
Healthcare · Drug Manufacturers - General
$30.79
Up+$0.79 (+2.63%)
Updated Nov 5, 2026, 5:35 AM
SID Score
7.4/10
Composite research score
Smart Money
55/100
Neutral
- Market cap
- 146.75B
- P/E ratio
- 14.94
- Dividend yield
- 5.59%
- 52-week range
- $23.62 – $31.06
- Volume
- 50.64M
- Avg. volume
- 68.83M
Price performance · PFE
PFE price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
PFE closed at $30.79 after 21 trading sessions, up 9.96% for the selected period.
- Last close
- $30.79
- Period change
- +9.96%
- Period low
- $27.82
- Period high
- $30.79
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $30.75 | $30.90 | $30.04 | $30.79 | 50.64M |
| Nov 3, 2026 | $30.68 | $31.06 | $29.89 | $30.00 | 53.06M |
| Nov 2, 2026 | $30.45 | $31.04 | $30.20 | $30.67 | 50.82M |
| Oct 30, 2026 | $30.51 | $30.67 | $30.14 | $30.52 | 45.49M |
| Oct 29, 2026 | $29.99 | $30.18 | $29.61 | $29.95 | 34.26M |
| Oct 28, 2026 | $29.49 | $29.815 | $29.22 | $29.45 | 27.26M |
| Oct 27, 2026 | $29.54 | $29.86 | $29.51 | $29.80 | 25.59M |
| Oct 26, 2026 | $30.00 | $30.305 | $29.715 | $29.79 | 25.66M |
| Oct 23, 2026 | $30.28 | $30.32 | $29.81 | $30.03 | 29.48M |
| Oct 22, 2026 | $30.045 | $30.44 | $29.88 | $30.42 | 28.7M |
| Oct 21, 2026 | $30.00 | $30.09 | $29.69 | $29.85 | 22.22M |
| Oct 20, 2026 | $29.67 | $30.25 | $29.59 | $30.11 | 34.44M |
| Oct 19, 2026 | $29.305 | $29.69 | $29.25 | $29.44 | 20.82M |
| Oct 16, 2026 | $29.72 | $29.74 | $29.42 | $29.58 | 28.63M |
| Oct 15, 2026 | $29.57 | $29.88 | $29.42 | $29.44 | 32.89M |
| Oct 14, 2026 | $28.60 | $29.49 | $28.55 | $29.21 | 39.37M |
| Oct 13, 2026 | $28.61 | $28.61 | $28.13 | $28.37 | 26.84M |
| Oct 12, 2026 | $28.42 | $28.495 | $28.28 | $28.40 | 18.56M |
| Oct 9, 2026 | $27.61 | $28.285 | $27.59 | $28.28 | 23.2M |
| Oct 8, 2026 | $27.90 | $28.00 | $27.475 | $27.82 | 44.43M |
| Oct 7, 2026 | $27.62 | $28.17 | $27.55 | $28.00 | 31.23M |
Latest PFE news
The latest Smart Investors Daily articles mentioning PFE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PFE research
Overview
Company profile and research snapshot.
Company profile
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $30.00
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 9, 2026 | JP Morgan | Neutral | — |
| Oct 8, 2026 | Cantor Fitzgerald | Neutral | — |
| Oct 6, 2026 | Scotiabank | Sector Outperform | — |
| Sep 10, 2026 | HSBC | Hold | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 30, 2026
Are Wall Street Analysts Predicting Pfizer’s Stock Will Climb or Sink?
Pfizer has surpassed the broader S&P 500 Index over the past year, and analysts are cautious about the stock’s prospects.
SeekingAlpha · Oct 30, 2026
Pfizer: Reality Check Ahead Of Earnings
Pfizer is downgraded from Buy to Hold as analyst sentiment turns increasingly bearish and growth prospects dim. Read more on PFE stock here.
Yahoo · Oct 30, 2026
How Investors May Respond To Pfizer (PFE) Phase 3 Cancer Trial Win
Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met the primary endpoint in relapsed or refractory multiple myeloma, while the FDA expanded approval of TALZENNA plus XTANDI for men with metastatic hormone sensitive prostate cancer with homologous recombination repair gene mutations. Together, the ELREXFIO data and earlier line TALZENNA plus XTANDI approval deepen Pfizer’s oncology portfolio in two hard to treat cancers, adding more potential uses for existing medicines...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
